



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,852	09/22/2000	Per Johan Lundberg	1103326-0686	1116
7470	7590	08/17/2004	EXAMINER	
WHITE & CASE LLP PATENT DEPARTMENT 1155 AVENUE OF THE AMERICAS NEW YORK, NY 10036			TRAN, SUSAN T	
			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 08/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/646,852	Applicant(s) LUNDBERG ET AL.	
	Examiner Susan T. Tran	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3-18,20 and 23-28 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3-18,20 and 23-28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of applicant's Request for Continued Examination filed 05/14/04, Notice of Appeal filed 03/05/04, and Amendment after Final filed 12/18/03.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/14/04 has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.

Art Unit: 1615

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 3, 6-18, 20 and 25-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351.

Nara teaches a controlled release composition comprising a drug-containing core coated with a coating composition containing a water-insoluble substance and a swellable polymer (abstract, column 1, lines 50-63). Drugs include omeprazole and lansoprazole, are mixed with excipient, such as sucrose or calcium phosphate (osmotic agent); binder; disintegrant, such as , sodium crosslinked carboxymethylcellulose or low-substitutional hydroxypropyl cellulose (swelling agent); and lubricant, including talc (alkaline additive) (column 3, lines 59-61; column 5, lines 36-52; and examples). Core can be in the form of granule, fine granule, or inert carrier particles include sucrose (column 5, lines 30-35, and 60-65). The water-insoluble substance contained in the coating composition includes ethyl cellulose, cellulose acetate, and Eudragit RS (column 4, lines 5-25; and column 6, lines 15-25). The coating composition further comprises talc (modifying agent) (column 6, lines 50-55; and example 3). The examples show the weight of coating composition is about 20-30% to the core. The coated core can be prepared in tablet or capsule form for oral administration (column 6, lines 56-65; and claim 7).

It is noted that Nara does not explicitly teach the weight ratio of the modifying agent to water-insoluble substance, as well as the amount of the alkaline additive and swelling agent in the core. However, generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is

Art Unit: 1615

evidence indicating such concentration is critical. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Thus, it would have been obvious for one of ordinary skill in the art to, by routine experimentation determine suitable amount of talc in the core composition as well as in the coating composition, because Nara teaches the release rate of the active ingredient is mainly in the small and large intestine without an enteric coating, while the release rate of the active ingredient is very limited in the stomach (column 1, lines 53-55; and column 7, lines 25-31), and because Nara teaches a coated formulation with low toxicity that can be safely used in human. The expected result would be a controlled-release composition comprising omeprazole in the core without enteric coating that can limit release of omeprazole in the stomach, but increases release in the small and large intestine.

Claims 4, 5 and 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nara et al. US 6,245,351, in view of Cotton et al. WO 98/54171.

Nara is relied upon for the reason stated above. Nara is deficient in the fact that it does not specifically teach magnesium salt of omeprazole.

Cotton teaches novel form of S-enantiomer of omeprazole, including S-omeprazole, and more specifically, magnesium salt of S-omeprazole trihydrate (hereafter, the compound) (see abstract, and page 1, lines 4-10). Cotton also teaches the compound is formulated into oral dosage form, e.g., capsule, tablet, and the like

Art Unit: 1615

(page 6, lines 15-30). The formulation is effective as a gastric acid secretion inhibitor and is useful as an anti-ulcer agent (page 6, lines 1-14).

Cotton does not explicitly teaches the compound having a crystallinity of more than 70%, however, Cotton teaches that the compound of his invention is highly crystalline, *i.e.*, having a higher crystallinity than any other form of magnesium salt of S-omeprazole in the prior art (page 3, lines 24 through page 4, lines 1-7). Therefore, the burden is shifted to applicant to show the compound taught by Cotton does not have the crystallinity being claimed. It is also noted that Cotton teaches the trihydrate form, *e.g.*, magnesium salt of S-omeprazole "trihydrate". However, applicant claims recite a generic form of magnesium salt of S-omeprazole with the transitional phrase "comprising of" permits any other form, including "trihydrate" taught by Cotton. Thus, it would have been obvious for one of ordinary skill in the art to modify the controlled release composition comprising a drug-containing core coated with a *non-enteric* coating composition using the magnesium salt of S-omeprazole trihydrate in view of the teaching of Cotton, because Cotton teaches the compound of his invention is more stable, easier to handle and store, easier to synthesize in a reproducible manner, because Cotton teaches the compound is most preferred in oral administration formulation, because Nara teaches a non-enteric coated formulation with low toxicity that can be safely used in human. The expected result would be a controlled-release composition comprising omeprazole in the core without enteric coating that can limit release of omeprazole in the stomach, but increases release in the small and large intestine.

Art Unit: 1615

Pertinent Arts

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Appelgren et al., Dahlander et al., Rudnic et al., Lundberg, and Edgren et al. are cited as of interest for the teachings of omeprazole dosage form.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan T. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-R from 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page, can be reached at (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

S. Tran
Patent Examiner
AU 1615

